Identification the Clinical Value of PLOD Family Members in Lung Adenocarcinoma: A Comprehensive Analysis

2021 ◽  
Author(s):  
Yiming Meng ◽  
Jing Sun ◽  
Guirong Zhang ◽  
Tao Yu ◽  
Haozhe Piao
Keyword(s):  
Lung Adenocarcinoma ◽  
Family Members ◽  
Comprehensive Analysis ◽  
Clinical Value

Role of DNA polymerases family members in cancer: The pan-cancer perspective.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 475-475
Author(s):  
Zhiwen Luo ◽  
Xinyu Bi ◽  
Xingang Bi
Keyword(s):  
Expression Pattern ◽  
Drug Target ◽  
Dna Polymerases ◽  
Family Members ◽  
Prognostic Biomarkers ◽  
Cancer Type ◽  
Sequencing Data ◽  
Clinical Value ◽  
Bioinformatics Analyses ◽  
Pan Cancer

475 Background: DNA polymerases family (DNA pols) has a lengthy reported significant influence on the initiation, development, and progress of cancer. However, the pan-cancer value of whole family members was poorly done. Our study intends to demonstrate the expression pattern and clinical cancer value of DNA pols members as prognostic biomarkers and a therapeutic target of pan-cancer. Methods: Comprehensive bioinformatics analyses were done using data from TCGA and CCLE. MultiCox regression was done to select tumor prognosis-related members. Nomogram was constructed to predict the overall survival (OS) across cancer patients. Transcription factor, GO, IPA, and GSEA enrichments were done to explore regulatory mechanisms and functions. Results: A total of 22 DNA pols were identified to have a potential to diagnostic value, and 10 DNA pols have a pan-cancer prognostic value under various stages, and cancer type, among which overexpression of 6 DNA-pols (POLA2, POLD1, POLD2, POLE2, POLE4, and POLQ) was found to be significantly related to worse outcomes regarding OS, while 4 DNA-pols (POLH, POLL, POLN, and REV1) significantly related to better outcomes. A 5-DNA pols based risk score (POLQ, POLD2, POLL, POLH, and REV1) was generated by MultiCox regression with a nomogram validated an accurate predictive efficacy. MYB Proto-Oncogene Like 2 (MYBL2) was identified as transcription factors of prognostic DNA pols in pan-cancer, and IPA mimic experiment reveals inhibiting MYBL2 could be a drug target to recover and balance the dysregulated expression pattern of DNA pols in pan-cancer. GO, IPA, and GSEA enrichments revealed functions and pathways altered by DNA pols in cancer, and the results were supported by pan-cancer cell sequencing data. Conclusions: DNA pols have a pan-cancer clinical value and can work as potential prognostic biomarkers. Furthermore, MYBL2 could be a drug target for pan-cancer.

scholarly journals Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer

2020 ◽  
Vol 21 (24) ◽  
pp. 9751
Author(s):  
Hung-Yu Lin ◽  
Chia-Jung Li ◽  
Ya-Ling Yang ◽  
Ying-Hsien Huang ◽  
Ya-Tze Hsiau ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Liver Cancer ◽  
Lysyl Oxidase ◽  
Primary Liver Cancer ◽  
Target Therapy ◽  
Family Members ◽  
Clinical Value ◽  
Ecm Remodeling ◽  
Liver Cancers ◽  
Advanced Stages

The lysyl oxidase (LOX) family members are secreted copper-dependent amine oxidases, comprised of five paralogues: LOX and LOX-like l-4 (LOXL1-4), which are characterized by catalytic activity contributing to the remodeling of the cross-linking of the structural extracellular matrix (ECM). ECM remodeling plays a key role in the angiogenesis surrounding tumors, whereby a corrupt tumor microenvironment (TME) takes shape. Primary liver cancer includes hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), ranked as the seventh most common cancer globally, with limited therapeutic options for advanced stages. In recent years, a growing body of evidence has revealed the key roles of LOX family members in the pathogenesis of liver cancer and the shaping of TME, indicating their notable potential as therapeutic targets. We herein review the clinical value and novel biological roles of LOX family members in tumor progression and the TME of liver cancers. In addition, we highlight recent insights into their mechanisms and their potential involvement in the development of target therapy for liver cancer.

scholarly journals SLC15A4 Serves as a Novel Prognostic Biomarker and Target for Lung Adenocarcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Hui Huang ◽  
Junwei Wang ◽  
Shibin Chen ◽  
HongJiang He ◽  
Yu Shang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Clinical Outcomes ◽  
Regulatory Networks ◽  
Molecular Mechanisms ◽  
Family Members ◽  
Human Lung Cancer ◽  
Survival Prediction ◽  
Aberrant Expression ◽  
Large Patient

BackgroundSLC15A family members are known as electrogenic transporters that take up peptides into cells through the proton-motive force. Accumulating evidence indicates that aberrant expression of SLC15A family members may play crucial roles in tumorigenesis and tumor progression in various cancers, as they participate in tumor metabolism. However, the exact prognostic role of each member of the SLC15A family in human lung cancer has not yet been elucidated.Materials and MethodsWe investigated the SLC15A family members in lung cancer through accumulated data from TCGA and other available online databases by integrated bioinformatics analysis to reveal the prognostic value, potential clinical application and underlying molecular mechanisms of SLC15A family members in lung cancer.ResultsAlthough all family members exhibited an association with the clinical outcomes of patients with NSCLC, we found that none of them could be used for squamous cell carcinoma of the lung and that SLC15A2 and SLC15A4 could serve as biomarkers for lung adenocarcinoma. In addition, we further investigated SLC15A4-related genes and regulatory networks, revealing its core molecular pathways in lung adenocarcinoma. Moreover, the IHC staining pattern of SLC15A4 in lung adenocarcinoma may help clinicians predict clinical outcomes.ConclusionSLC15A4 could be used as a survival prediction biomarker for lung adenocarcinoma due to its potential role in cell division regulation. However, more studies including large patient cohorts are required to validate the clinical utility of SLC15A4 in lung adenocarcinoma.

scholarly journals Systemic analyses of expression patterns and clinical features for GIMAPs family members in lung adenocarcinoma

Aging ◽  
2020 ◽  
Vol 12 (20) ◽  
pp. 20413-20431
Author(s):  
Sisi Deng ◽  
Zhi Zhang ◽  
Xiaoli Lu ◽  
Qi Zhou ◽  
Shilin Xia ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Clinical Features ◽  
Expression Patterns ◽  
Family Members
Sign in / Sign up

Export Citation Format

Share Document